Table 1. Characteristics of the included studies.

study	country	patients					Interventions		outcomes
		number	age average	gender	cancer type	chemotherapy drug	T	C
Chalermchai 2010[13]	Thailand	56	56.7(range,26–82)	female(57%) male(43%)	breast cancer:17 colorectal cancer:39	capecitabine	400 mg/d po	200 mg/d po	(2),(3),(4),(5)
Corrie 2012[10]	UK	106	73(range,42–87)	female(64%) male(36%)	colorectal cancer:68 breast cancer:38	capecitabine	150 mg/d po	placebo	(1),(2),(5),(6),(7),(8)
Fang 2010[14]	China	56	61(range,38–78)	female(48%) male(52%)	breast cancer:18 colorectal cancer:28 stomach cancer:10	capecitabine	300 mg/d po	-	(1),(2)
Gruenigen 2010[12]	USA	34	64(range,45–81)	female(100%)	ovarian/peritoneal cancer:25 endometrial cancer:8 breast cancer:1	pegylated liposomal doxorubicin	200 mg/d po	placebo	(1),(2), (6), (9)
Kang 2010[11]	Korea	360	56(range,20–75)	female(37.5%) male(62.5%)	stomach cancer:132 colon cancer:215 biliary tract cancer:12 duodenum cancer:1	capecitabine	200 mg/d po	placebo	(1),(2),(4)
Total		612	62.1(range,20–87)

Abbreviation: T, treatment group; C, control group; –, no treatment; po. per os.

Outcomes reported:(1)Incidence of all grades HFS; (2)Incidence of grade 2 or worse HFS; (3)Time to development of grade 2 or worse HFS; (4)Factors affecting development of HFS;(5)Tumor response;(6)Quality of life;(7)Chemotherapy drug dose modification;(8)Progression-free survival;(9)Incidence of Adverse Events excluding HFS.